DNTH
Dianthus Therapeutics, Inc.NASDAQHealthcare$86.00+1.70%ClosedMarket Cap: $3.30B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
6.59
P/S
1622.64
EV/EBITDA
-18.71
DCF Value
$-3.08
FCF Yield
-3.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-8739.3%
Net Margin
0.0%
ROE
0.0%
ROA
0.0%
ROIC
0.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $284.0K | $97.9M | $2.59 |
| FY 2025 | $2.0M | $-162.3M | $-4.20 |
| Q3 2025 | $396.0K | $-36.8M | $-0.97 |
| Q2 2025 | $193.0K | $-31.6M | $-0.88 |
Analyst Ratings
View AllWedbushOutperform
2026-03-12BairdOutperform
2026-03-10Raymond JamesStrong Buy
2026-03-10Clear StreetBuy
2026-03-10OppenheimerOutperform
2026-03-09Trading Activity
Insider Trades
View AllSavitz Ryanofficer: EVP, CFO & CBO
SellWed Apr 01
Savitz Ryanofficer: EVP, CFO & CBO
SellWed Apr 01
Savitz Ryanofficer: EVP, CFO & CBO
SellWed Apr 01
Savitz Ryanofficer: EVP, CFO & CBO
SellWed Apr 01
Savitz Ryanofficer: EVP, CFO & CBO
SellWed Apr 01
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.21
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.